Catalyst Wire Dossier Catalyst Wire Dossier

Furmonertinib

furmonertinib
Drug timelines are a Plus or Pro feature.

38 regulatory and trial events tracked for Furmonertinib, covering 2021-07-21 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy [Phase 2]

See pricing